PIN16 HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH HEPATITIS A IN A US COMMERCIALLY INSURED POPULATION  by Eisenberg, D et al.
13th Euro Abstracts A433
PIN16
HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH 
HEPATITIS A IN A US COMMERCIALLY INSURED POPULATION
Eisenberg D1, Changolkar A2, Misurski D2
1HealthCore, Wilmington, DE, USA; 2GSK, Philadelphia, PA, USA
OBJECTIVES: While the economic burden associated with acute hepatitis a outbreaks 
studied, the impact on health care utilization and associated cost has not been exam-
ined over one year in a commercially insured population. METHODS: An observa-
tional, retrospective study using HealthCore Integrated Research Database (HIRDSM) 
medical and pharmacy claims (January 1, 2004–December 31, 2009) was conducted. 
Index date was assigned based on the ﬁ rst medical claim for hepatitis a (intake period 
January 1, 2005—December 31, 2008). The control group did not have hepatitis. The 
index date assigned was of the hepatitis a match. Subjects had continuous plan eligibil-
ity for ≥12 months pre- and post-index. Descriptive statistics, including t-tests and 
chi-square analyses were used. RESULTS: Comparisons (n = 2331 for each cohort) 
were signiﬁ cant (p < 0.01). Post-index inpatient hospitalization occurred for 482 
(20.7%) hepatitis a patients and 193 (8.3%) controls. Associated mean costs (+SD) 
were $5,401 (+/−$30,567) and $1,929 (+/−$23,282), respectively. Emergency room 
(ER) services occurred in 382 (16.4%) hepatitis a subjects versus 277 (11.9%) con-
trols. Mean costs were $231 (+/−$816) and $139 (+/−$604), respectively. The mean 
number of outpatient services for the hepatitis a group was 21.5 (+/−22.1) versus 14.7 
(+/−18.2) for controls with associated mean costs of $4,985 (+/−$14,936) and $2,948 
(+/−$14,624), respectively. The mean number of physician visits were 9.1 (+/−9.9) and 
5.5 (+/−7.4) for each group, respectively [mean costs = $1185 (+/−$3712) and $675 
(+/−$2183)]. There were 20.13 (+/−24.1) and 19.37 (+/−24.5) pharmacy claims with 
mean costs of $2255 (+/−$5828) and $1420 (+/−$2656), in the hepatitis a and con-
trols. Mean total associated costs were $14,056 (+/−$42,666) and $7,111 (+/−
$30,519) in the hepatitis a and controls. CONCLUSIONS: In the 12-month post-index 
period hepatitis a patients had greater total health care utilization and costs compared 
to controls suggesting hepatitis a is associated with an increase in health care utiliza-
tion and costs.
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IMPACT OF YELLOW FEVER OUTBREAKS IN BRAZIL, 2000–2009
Ramos CG, Ferreira Da Silva AL
Universidade Federal do Rio Grande do Sol, Porto Alegre, Brazil
OBJECTIVES: To evaluate the health and economic impact of the expansion of YF 
virus in Brazil in the period of 2000–2009. METHODS: The perspective of study was 
the public health care system. We evaluated the direct costs of hospitalization and YF 
vaccine. Data source was the public ofﬁ cial national information on YF cases and YF 
vaccination from Brazilian Ministry of Health. We assumed that all cases required 
hospitalization and that all fatalities required intensive care unit (ICU) hospitalization 
and dialysis. All values were referent to December of 2009. The values of hospitaliza-
tion by yellow fever, ﬁ ve days ICU hospitalization and ﬁ ve days dialysis paid by public 
health system were, respectively, R$174.45 (c79.3); R$2393.60 (c1088) and R$ 557.1 
(c253.23). RESULTS: During the evaluated period, YF virus circulation was detected 
in eight states previously YF free. There were 320 cases of YF with lethality rate of 
46.5%. The cumulative population vaccinated was 90,906,675 individuals. The YF 
related hospitalization cost was R$ 495,478.30 (c225,217.41) and YF vaccine cost 
was R$89,997,608 (c40,908,003.75) within the 10 year period evaluated. CONCLU-
SIONS: Even in areas with susceptive population there were few cases of yellow fever. 
However, the signiﬁ cant clinical impact of the disease was due to its high lethality. 
Despite the severity of yellow fever, hospitalization costs were modest in the study 
period. The main cost was with the vaccine, the only form of prevention and control 
of disease. Thereby, it is necessary to evaluate the ﬁ nancial impact of vaccinating the 
areas that still have no evidence of the yellow fever virus, since there seems to be an 
expansion tendency of YF virus circulation to the country as a whole and the vaccina-
tion could prevent YF cases and deaths.
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A PILOT COST-OF-ILLNESS STUDY ON LONG TERM COMPLICATIONS/
SEQUELAE FOLLOWING ACUTE OTITIS MEDIA (AOM) IN BELGIUM
Strens D1, Dhooge I2, Knerer G3, Van Vlaenderen I1
1Deloitte, Diegem, Belgium; 2Ghent University Hospital, Ghent, Belgium; 3GlaxoSmithKline 
Biologicals, Wavre, Belgium
OBJECTIVES: A study was carried out to assess the economic burden associated with 
complications and/or long -term sequelae of AOM. This pilot study was done to assess 
feasibility to extend to a larger sample. METHODS: A retrospective patient chart 
review was performed in one Belgian center to obtain data on medical consumption 
related to the management of complications/sequelae of AOM. Data were collected 
for 10–15 years from the ﬁ rst AOM event onwards. Patients were eligible if they were 
between 10 and 20 years old with minimum 9 years of follow up data available and 
experienced a complication of AOM. Data on demographics, occurrence and type of 
complication, management of AOM, complications and sequelae were collected per 
year. Direct costs were calculated by multiplying each item of resource use with its 
unit cost (2010 in c) using the Belgian public health care payer’s perspective. Average 
(SD) yearly cost per patient, average yearly cost pre-complication, average cost during 
the year of complication, average yearly cost post-complication were calculated. 
RESULTS: Twenty-ﬁ ve patients were recruited in this pilot study. Complications were 
chronic suppurative OM with cholesteatoma, chronic perforation of the tympanic 
membrane and sensorineural hearing loss. The average yearly cost per patient was 
c966(SD:1579) with following components; hearing aid devices (c381(SD:1356)), 
hospitalizations (c298(SD:250)), outpatient procedures (c121(SD:107)), visits (c91 
(SD:183)), tests (c48(SD:46)) and drugs (c25(SD:89)). a complication occurred on 
average 5.3 years (SD: 2.9) after the ﬁ rst AOM event. Average annual cost pre-com-
plication was c232(SD:218), with outpatient procedures as main cost drivers. Average 
cost of complication per annum was c2808(SD:4827), average yearly cost post-
complication was c1593(SD:3366). As from occurrence of complication onwards costs 
are mainly driven by hospitalizations and hearing aid devices. CONCLUSIONS: Long 
term complications/sequelae of AOM result in considerable costs for the health care 
payer, mainly driven by hospitalizations, and hearing aid devices.
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HEPATITIS C BURDEN IN RUSSIA
Omelyanovsky VV, Avksentieva MV, Krysanov I, Ivakhnenko O
Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Moscow, 
Russia
OBJECTIVES: To assess social and economic burden of a hepatitis Ñ infection in 
Russian Federation. METHODS: Cost of illness analysis was performed. Available 
data on epidemiology of hepatitis C infection in Russian Federation has been analyzed. 
Experts were surveyed to describe common practice of treating patients with acute 
and chronic hepatitis C. Costs of medical care were calculated from the health care 
system point of view. RESULTS: State registration of hepatitis C infection has been 
launched in 1994. The incidence of acute hepatitis C is decreasing while there is 
increase in chronic hepatitis C new cases. Number of people with asymptomatic virus 
carriage was increasing till 2001 and has been slowly decreasing since then. There is 
no data about hepatitis C prevalence in Russia. Expected economic burden was cal-
culated on the basis of several assumptions: 1) only new cases of chronic hepatitis C 
are treated; 2) all new cases of acute hepatitis C are hospitalized, all new cases of 
chronic hepatitis C get hospital treatment ﬁ rst, then out-patient treatment; 3) and only 
15 % of all patients with chronic hepatitis C receive treatment with pegylated inter-
ferons and ribavirin reimbursed from national health care system. CONCLUSIONS: 
Based on these assumptions expected economic burden of hepatitis C infection in 
Russian Federation is about c0,16 million.
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PSEUDOMONAS AERUGINOSA RELATED ECONOMIC BURDEN 
STRATIFIED BY COMORBIDITY IN CYSTIC FIBROSIS PATIENTS
Sansgiry S1, Joish V2, Boklage S2, Goyal RK1, Seal B2, Sethi S3
1University of Houston, Houston, TX, USA; 2Bayer, Wayne, NJ, USA, 3University at Buffalo, 
SUNY, Buffalo, NY, USA
OBJECTIVES: To determine if the average cost of medical care among cystic ﬁ brosis 
(CF) patients post Pseudomonas aeruginosa (PA) infection is different for those with 
underlying comorbid conditions. METHODS: MarketScan claims database which 
captures person-speciﬁ c direct medical utilization, expenditures, and enrollment from 
approximately 150 payers was used to conduct a retrospective cross-sectional study. 
CF subjects with an initial claim for a PA infection were identiﬁ ed using international 
classiﬁ cation of diseases diagnosis codes of 277.0 and 482.1, respectively. Demo-
graphic information from administrative claims and health care utilization and costs 
from medical and pharmacy claims were extracted for 12 months post initial PA claim. 
All resource use and costs were annualized and compared among subjects with comor-
bidity and the overall sample using SAS version 9.2. RESULTS: Of the 347 CF subjects 
with PA infection that met the study criteria, 79% had multiple co-morbidities, 67% 
had pancreatic insufﬁ ciency, followed by chronic sinusitis (19%), CF-related diabetes 
(13%), bronchiectasis (7%), and osteoporosis (5%). Subjects had a mean age of 20 
years (SD 15.4) and 47.8% were females. As compared to an average CF subject, 
those with multiple co-morbidities had signiﬁ cantly higher (P < .05) overall pharmacy 
claims (mean 39 vs. 44) and cost (mean $20,673 vs. $24,121, median $17,121 vs. 
$22,344). Overall cost in subjects with CF-related diabetes (mean = $66,364 and 
median = $60,759) and osteoporosis (mean = $88,703 and median = $55,686) was 
signiﬁ cantly (P < 0.05) greater as compared to an average CF subject (mean = $51,821 
and median = $36,046). Among CF-related diabetic subjects and osteoporosis subjects, 
signiﬁ cantly (P < 0.05) higher outpatient visits and pharmacy claims and higher 
inpatient costs contributed to overall increase in health care costs compared to the 
average CF subject. CONCLUSIONS: Overall post-PA infection medical care costs 
were higher in comorbid cohorts compared to the overall CF sample. Future research 
needs to determine cost-effectiveness of PA infection treatment for among these comor-
bid conditions.
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EMPIRIC ANTIBIOTIC PRRESCRIBING IN SUBJECTS WITH INFLUENZA 
IN A UNITED STATES COMMERCIALLY INSURED POPULATION
Misurski DA1, Lipson D2, Changolkar AK1
1GlaxoSmithKline, Philadelphia, PA, USA; 2GlaxoSmithKline, King of Prussia, PA, USA
OBJECTIVES: To evaluate empiric antibiotic prescribing and associated costs in com-
mercially insured members with seasonal inﬂ uenza. METHODS: This retrospective 
analysis was conducted using Impact National Benchmark Database pharmacy, 
medical, and conﬁ nement claim data (01/01/2004 through 12/31/2009). The index 
date was deﬁ ned as the ﬁ rst inﬂ uenza (ICD-9:487.xx) claim, within the intake period 
(01/01/2005 through 11/30/2009). Subjects had continuous eligibility for ≥12 months 
prior to and one month after the index date. We used the ﬁ rst inﬂ uenza event only. 
Subjects with a pre-index diagnosis requiring antibiotic treatment were excluded. 
